Laura Steponavičienė1, Rūta Briedienė2, Rasa Vansevičiūtė-Petkevičienė3, Daiva Gudavičienė-Petkevičienė4, Ieva Vincerževskienė5. 1. Outpatient Department, National Cancer Institute, Vilnius, Lithuania. 2. Department of Radiology, National Cancer Institute, Vilnius, Lithuania Faculty of Medicine, Vilnius University, Lithuania. 3. Outpatient Department, National Cancer Institute, Vilnius, Lithuania Faculty of Medicine, Vilnius University, Lithuania. 4. Department of Breast Surgery and Oncology, National Cancer Institute, Vilnius, Lithuania. 5. Laboratory of Clinical Oncology, National Cancer Institute, Vilnius, Lithuania.
Abstract
ABSTRACT BACKGROUND: Breast cancer is the most frequent oncological disease as well as the leading cause of cancer death among women worldwide. Decline in mortality in economically strong countries is observed. This decline is mostly related to early diagnosis (an improvement in breast cancer awareness and the mammography screening program (MSP)) and a more effective treatment. In the end of 2005, MSP started in Lithuania. The main aim of this article is to evaluate the breast cancer mortality during 22 years in Lithuania, as well as changes before the start of the MSP and during its implementation, in order to assess the influence of the MSP on mortality. MATERIALS AND METHODS: Analysis is based on data from the population-based Lithuanian Cancer Registry. Analysis of changes in mortality includes the period from 1998 to 2019. Age standardized mortality rates are calculated for assessment of changes. Joinpoint regression analysis is used. RESULTS: Applying the segmental regression model, it was found that during the study period mortality was statistically significantly decreasing by -1.1% each year. Mortality among women under the age of 50 decreased both before and during the implementation of MSP. Mortality in the target population also was already decreasing until the implementation of the program, but a significant reduction in mortality was observed in this group since 2006. CONCLUSIONS: Overall breast cancer mortality is decreasing in Lithuania. After the implementation of MSP the largest reduction in mortality was observed in the target population, however, it is not as pronounced as it could be with the well-organized MSP.
ABSTRACT BACKGROUND: Breast cancer is the most frequent oncological disease as well as the leading cause of cancer death among women worldwide. Decline in mortality in economically strong countries is observed. This decline is mostly related to early diagnosis (an improvement in breast cancer awareness and the mammography screening program (MSP)) and a more effective treatment. In the end of 2005, MSP started in Lithuania. The main aim of this article is to evaluate the breast cancer mortality during 22 years in Lithuania, as well as changes before the start of the MSP and during its implementation, in order to assess the influence of the MSP on mortality. MATERIALS AND METHODS: Analysis is based on data from the population-based Lithuanian Cancer Registry. Analysis of changes in mortality includes the period from 1998 to 2019. Age standardized mortality rates are calculated for assessment of changes. Joinpoint regression analysis is used. RESULTS: Applying the segmental regression model, it was found that during the study period mortality was statistically significantly decreasing by -1.1% each year. Mortality among women under the age of 50 decreased both before and during the implementation of MSP. Mortality in the target population also was already decreasing until the implementation of the program, but a significant reduction in mortality was observed in this group since 2006. CONCLUSIONS: Overall breast cancer mortality is decreasing in Lithuania. After the implementation of MSP the largest reduction in mortality was observed in the target population, however, it is not as pronounced as it could be with the well-organized MSP.
Authors: J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray Journal: Eur J Cancer Date: 2013-02-26 Impact factor: 9.162
Authors: Elizaga N Ascunce; C Moreno-Iribas; A Barcos Urtiaga; E Ardanaz; M Ederra Sanz; J Castilla; N Egüés Journal: J Med Screen Date: 2007 Impact factor: 2.136